PFE is 32% below fair value and in buy zone. Consider adding to your position.
QuantHub Research: Investment Thesis
Maturing Phase
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating margin of 24.7%, Pfizer faces near-term earnings pressure with a 509% decline in earnings and a 1.2% revenue decline in the most recent quarter, primarily due to COVID-19 product sales normalization and patent expirations. The stock trades at a trailing and forward P/E of 19.26 and an EV/EBITDA of 12.87, which is cheap relative to its five-year history, supporting a fair value estimate of $35.65 and a 35.4% upside. However, the current analyst consensus is Hold, reflecting caution amid regulatory risks and revenue headwinds. Pfizer's valuation reflects a mature business with stable margins but limited near-term growth, making it attractive for investors seeking defensive exposure with moderate upside potential.
Pfizer is trading cheaply relative to its historical valuation due to near-term revenue and earnings declines driven by COVID-19 product normalization and patent expirations. The stock's P/E of 19.26 and EV/EBITDA of 12.87 reflect market caution about growth sustainability and regulatory risks. Analyst sentiment is mixed with a Hold consensus and no unified price target, indicating uncertainty about the company's ability to offset headwinds with pipeline growth and operational improvements.
12–18 Month Outlook
In 18 months, Pfizer is expected to experience continued revenue pressure with guidance for 2026 revenues between $59.5 billion and $62.5 billion, reflecting ongoing COVID-19 product declines and loss-of-exclusivity impacts. Earnings are projected to remain stable but under pressure with adjusted EPS guidance of $2.80 to $3.00. The stock may face limited upside near term due to these headwinds, though pipeline progress and operational efficiencies could provide some offset.
Bull vs Bear
Bull Case
Pfizer's non-COVID operational revenue grew 6% in 2025, driven by strong performance in key products such as Eliquis, which grew 13% year-over-year.
The company has a robust pipeline with promising assets in Oncology, RSV (Abrysvo), and recently acquired businesses that could drive future growth beyond 2026.
Management has demonstrated strategic discipline by divesting non-core businesses and increasing R&D and digital innovation investments, positioning Pfizer as a science-driven company.
The stock trades at a discount to its five-year historical valuation, offering a 35.4% upside to the fair value estimate of $35.65.
Pfizer maintains strong margins with a gross margin of 70.3% and operating margin of 24.7%, supporting cash flow generation and shareholder returns.
Bear Case
Revenue declined 1.2% year-over-year in the most recent quarter, reflecting ongoing challenges from COVID-19 product sales normalization and patent expirations.
Earnings declined sharply by 508.9% year-over-year in the most recent quarter, indicating significant near-term profitability pressure.
Regulatory risks such as Most Favored Nation pricing and potential pricing reforms could reduce U.S. drug prices and pressure margins.
The company faces patent expirations and loss-of-exclusivity headwinds estimated at approximately $1.5 billion in 2026, which could further depress revenues.
Integration risks from acquisitions and execution risks in the pipeline could delay or reduce expected future growth.
Leadership & Competitive Position
Albert Bourla
Tenure5 yrs
Beats guidance75% of qtrs
Capital allocationGood
Albert Bourla has led Pfizer since January 2019, driving a strategic transformation focused on science and innovation. He has a long tenure at Pfizer with over 30 years of experience and has held key leadership roles including COO and Group President. Bourla has overseen portfolio optimization, increased R&D investment, and led the spin-off of the consumer healthcare business. He is recognized as a top pharmaceutical CEO and holds multiple board and industry leadership positions.
Competitive Moat
stable
intangible assetsbrandcost advantage
Pfizer holds leading market positions in vaccines, oncology, and primary care segments, with key products like Eliquis generating nearly $8 billion in annual sales. The company operates one reportable segment with three operating segments, maintaining strong U.S. revenue dominance.
Competitors: Johnson & Johnson (JNJ), Merck & Co. (MRK), Novartis (NVS), Roche (RHHBY)
Disruption: Medium due to patent expirations and pricing pressures, but mitigated by pipeline and scale.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
19.26x
22.48x
24.1x
14.42x
187.62x
P/S
2.39x
3.12x
3.28x
2.39x
4.72x
P/FCF
16.5x
20.53x
25.06x
10.86x
213.39x
P/S 2.39x vs 5yr range 2.39-4.72x (P25=2.79x, median=3.28x, P75=3.74x)
The release will provide updated guidance and insight into pipeline progress, cost management, and revenue trends post-COVID normalization.
high
2026-Q3
Regulatory Pricing Policy Updates
Potential implementation of Most Favored Nation pricing or other U.S. drug pricing reforms could materially impact revenue and margins.
medium
2026-Q4
Pipeline Clinical Trial Readouts
Data from key oncology and vaccine candidates could drive investor sentiment and valuation re-rating.
medium
Risks
Regulatory Pricing Pressure
high
Policies such as Most Favored Nation pricing could force Pfizer to lower U.S. drug prices, significantly reducing revenue and margin flexibility.
Patent Expirations and LOE
high
Loss of exclusivity on key drugs is expected to reduce revenues by approximately $1.5 billion in 2026, pressuring top-line growth.
Pipeline Execution Risk
medium
Delays or failures in clinical trials for new products could impair future growth prospects and investor confidence.
COVID-19 Product Revenue Decline
medium
Continued normalization of COVID-19 vaccine and treatment sales will reduce overall revenue compared to pandemic peak levels.
Growth Engines
Oncology portfolioscaling
The oncology market is large and growing, with Pfizer's portfolio including key drugs like Ibrance and biosimilars contributing to operational growth.
Vaccines including RSVearly
Vaccines remain a significant growth area, especially with new products like Abrysvo targeting respiratory syncytial virus, addressing a large unmet medical need.
Established productsmature
Pfizer's established products generate steady revenue but face patent expirations and competitive pressures, limiting growth potential.
Management confirmed revenue guidance of $59.5 to $62.5 billion and adjusted EPS of $2.80 to $3.00, indicating stable margins but ongoing revenue headwinds.
2025-12-10
Eliquis Sales Grow 13% Year-Over-Year
Strong growth in Eliquis contributed to offsetting some COVID-19 revenue declines and demonstrated strength in Pfizer's oncology portfolio.
2025-11-05
Pfizer Reports 1.2% Revenue Decline in Most Recent Quarter
The decline reflects ongoing COVID-19 product normalization and patent expirations, highlighting near-term challenges.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is PFE undervalued?
Yes, PFE appears undervalued at the current price of $25.70, trading below our fair value estimate of $33.85 (+32% upside). QuantHub considers this a buy zone.
What is PFE's fair value?
QuantHub Research estimates PFE's fair value at $33.85 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for PFE?
Regulatory Pricing Pressure: Policies such as Most Favored Nation pricing could force Pfizer to lower U.S. drug prices, significantly reducing revenue and margin flexibility. Patent Expirations and LOE: Loss of exclusivity on key drugs is expected to reduce revenues by approximately $1.5 billion in 2026, pressuring top-line growth. Pipeline Execution Risk: Delays or failures in clinical trials for new products could impair future growth prospects and investor confidence.
What is the bull case for PFE?
Pfizer's non-COVID operational revenue grew 6% in 2025, driven by strong performance in key products such as Eliquis, which grew 13% year-over-year. The company has a robust pipeline with promising assets in Oncology, RSV (Abrysvo), and recently acquired businesses that could drive future growth beyond 2026. Management has demonstrated strategic discipline by divesting non-core businesses and increasing R&D and digital innovation investments, positioning Pfizer as a science-driven company. The s